Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Unresectable or metastatic pancreatic cancer~* Persistent cancer after at least one prior standard of care chemotherapy for advanced stage disease~* 18 years of age and older~* ECOG performance status of 0 or 1~* Life expectancy greater than 3 months~* Satisfactory organ and bone marrow function~* Meets blood coagulation parameters~* Male and Female subjects of reproductive potential agree to use approved contraceptive methods~Exclusion Criteria:~* Participation in a therapeutic investigational study within 4 weeks prior to the screening visit~* Anticipated need for systemic chemotherapy within 2 weeks before apheresis and infusion~* Active invasive cancer other than pancreatic cancer~* HIV, HCV, or HBV infections~* Active autoimmune disease requiring immunosuppressive therapy within 4 weeks prior to screening visit, with exception of thyroid replacement~* Ongoing or active infection~* Planned concurrent treatment with systemic high dose corticosteroids~* Patients requiring supplemental oxygen therapy~* Prior therapy with gene modified cells~* Previous experimental therapy with SS1 moiety, murine or chimeric antibodies~* History of allergy to murine proteins~* History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40)~* Clinically significant pericardial effusion, CHF, or cardiovascular condition that would preclude assessment of mesothelin induced pericarditis or that may worsen as a result of toxicities expected for this study~* Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CART-meso-19 T cells (Type: EXPERIMENTAL): A single dose of CART-meso-19 T cells (combination therapy with CART-meso and CART19 cells) will be administered intravenously as two separate infusions. The dose is 1-3x107/m2 (Cohort 1) or 1-3x108/m2 (Cohort 2) CART positive cells. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures in the outpatient setting.

Based on this trial design, predict the completion outcome and termination type (if applicable).